Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$39.1B
165M shares
52-week range
$154.50 – $251.36
86% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NYSE
CS
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
www.iqvia.comNo one on the platform currently holds IQV.
| Institution | Shares | Reported |
|---|---|---|
| Appaloosa LPas of 2025-12-31 | 280,000 | $63.1M |
| Renaissance Technologiesas of 2025-06-30 | 103,047 | $16.2M |
No one on the platform has traded IQV yet.
| 47,119 |
| $8.0M |
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $17.4B | +7.5% | $12.95 | $12.78–$13.07 | 18.4× | 13 |
| 2027 | $18.4B | +5.8% | $14.38 | $13.86–$14.98 | 16.5× | 14 |
| 2028 | $19.5B | +5.8% | $16.10 | $14.03–$18.67 | 14.8× | 8 |
| 2029 | $20.8B | +6.8% | $18.31 | $18.03–$18.93 | 13.0× | 6 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $31.8B |
| — |
| HLNHaleon plc | $10.11 | -1.65% | $44.5B | — |
| HUMHumana Inc. | $366.61 | +0.33% | $44.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$IQV Hearing whispers that OZSC is bringing in a seasoned VP of International Sales to lead global expansion for their subsidiary lines. Dedicated sales leadership is going to transform the revenue baseline! 🔥🚀
View on StockTwits ↗Made a bunch of changes to my portfolio today: - Closed the last of my $GOOG position from last year, rolling into LEAPS - closed out of $FIG Options for 50%. Still have shares and will add on dips. - closed $IQV position off of ER beat - decided to keep $OKLO the risk reward is worth - added $AMD for earnings 🪶🪶🪶
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-28-iqvia-holdings-inc-stock/ $IQV IQVIA Earnings Transcript
View on StockTwits ↗$IQV I unfortunately had to exit this position with, great gains
View on StockTwits ↗$IQV Positive (84%): shares face upward price pressure because the reported beat and guidance increase imply that current revenue, earnings, and cash-flow expectations are too low. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/55f9dd646dbc05aa?utm_source=stocktwits&utm_medium=story_url
View on StockTwits ↗$IQV (+10.2% pre) IQV: Revenue and earnings grew strongly in Q2 2026, prompting raised full-year guidance https://ooc.bz/l/108842
View on StockTwits ↗$IQV Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.54 down -0.65% YoY • Reported revenue of $4.37B up 8.74% YoY • IQVIA Holdings Inc. is raising its full-year 2026 guidance for revenue to between $17,275 million and $17,475 million, Adjusted EBITDA to $4,000-$4,050 million, and Adjusted Diluted EPS to $12.80-$13.00.
View on StockTwits ↗Institutional activity alert! $IQV sees $2M+ Call flow as smart money watches key support! Life sciences leader IQVIA ($IQV) trades at $201.45, down -1.23%, while absorbing short-term selling pressure around key horizontal demand levels. A notable options flow signal emerged with $2M+ in IQV Call activity, suggesting potential institutional positioning. The key now is whether buyers continue defending this support zone. Every move has a reason. Follow the clues. A confirmed breakout above resistance could trigger the next momentum expansion.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.